Opinion

Video

Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments

Author(s):

Brian Keegan, MD, PhD,Giselle Mosnaim, MD

Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE pathway, and the need for new therapies addressing the IgG pathway.

Video content above is prompted by the following:

  • A significant percentage (30%-50%) of patients are still symptomatic with chronic spontaneous urticaria while on certain recommended doses. What do you believe accounts for this high number of patients who are not responding adequately?
    • Patients have to come in for first 3 doses because this a biologic. Is this preferred? Is there a burden on these patients?
    • Said prescription targets the IgE pathway, but a significant percentage of patients have IgG antibodies as part of their disease pathophysiology. What do you do in your patients who do not respond to this prescription?
    • Why is it imperative to develop new treatments that target the IgG pathway?
Related Videos
Raj Chovatiya, MD, PhD, MSCI.
Related Content
Alopecia areata. | Image Credit: cattyphoto - stock.adobe.com
April 29th 2025

Study Highlights Unmet Needs in Measuring Patient Experiences in Alopecia Areata

Cameron Santoro
Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.
Dupilumab. | Image Credit: Semi - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Dupilumab Treatment for Patients With CSU: Insights From Jason Hawkes, MD, MS

Maddi Hebebrand
Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron Pharmaceuticals) in the management of chronic spontaneous urticaria (CSU), a condition with limited therapeutic options over the past decade.
Urticaria allergy. | Image Credit: Alex Pios - stock.adobe.com
April 23rd 2025

Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions

Cameron Santoro
Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Chronic hand eczema. | Image Credit: IIIRusya - stock.adobe.com
April 22nd 2025

Chronic Hand Eczema Has Significant Impacts on Patients' Lives, Survey Reveals

Cameron Santoro
Dermatology providers reported strong impacts on the work and home life of patients with moderate to severe chronic hand eczema, a manifestation of atopic dermatitis.
FDA Approved. | Image Credit: Tada Images - stock.adobe.com
April 18th 2025

FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade

Cameron Santoro
Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Skin hives. | Image Credit: Алексей Филатов - stock.adobe.com
April 16th 2025

Complete Responses Seen With Emerging Therapies for Chronic Spontaneous Urticaria

Cameron Santoro
There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and barzolvolimab showing complete response in patients, particularly among those who are difficult to treat.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo